Loading…
Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5
Objective To study the impact of definitions of various treatment extension criteria on the proportion of patients who could be extended at their first visit after the loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration (nAMD). Methods Patients with nAMD initia...
Saved in:
Published in: | Eye (London) 2024-10, Vol.38 (14), p.2737-2743 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c326t-978850c30178279d1790daf5d81b8439542c5ff3d6059a071334ac8bf47f9a8d3 |
container_end_page | 2743 |
container_issue | 14 |
container_start_page | 2737 |
container_title | Eye (London) |
container_volume | 38 |
creator | Thottarath, Sridevi Gurudas, Sarega Chandak, Swati Patel, Praveen J. Kotagiri, Ajay Pearce, Ian McKibbin, Martin Menon, Geeta Burton, Benjamin J. L. Talks, James Grabowska, Anna Ghanchi, Faruque Gale, Richard Karatsai, Eleni Chandra, Shruti Sivaprasad, Sobha |
description | Objective
To study the impact of definitions of various treatment extension criteria on the proportion of patients who could be extended at their first visit after the loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration (nAMD).
Methods
Patients with nAMD initiated on the loading phase of three intravitreal doses of 2 mg aflibercept in routine clinical practice were recruited from December 2019 to August 2021. The response to the loading phase was assessed at approximately 8 weeks post-loading (up to 140 days from first injection) based on different definitions of response. The proportion of patients that qualify for interval extension based on different clinical trial criteria was also evaluated.
Results
A total of 722 patients with visual acuity (VA) and optical coherence tomography (OCT) scans done at all 4 visits were included. Of these 32.4% of eyes responded with complete macular fluid resolution after the first injection with no recurrence through the loading phase (super-responders) while 26.9% had persistent macular fluid in all 4 visits (true non-responders). The rest were considered suboptimal responders. Change in VA showed marked variations within each of these categories of fluid resolution. For extension of next treatment interval, if presence of any macular fluid at the post-loading visit is the only criteria considered, about 50% could be extended to 8 weeks. If both VA worsening by ≥5 letters and a > 25 μm increase in central sub-field thickness (CST) are considered, 90% will be eligible for interval extension.
Conclusion
Clinical trial designs and pre-defined treatment extension/shortening criteria determine the proportion of patients requiring treatment in the post-loading visit. The short and long-term impact of interval extension immediate post-loading on visual outcome in clinical practice is unknown. |
doi_str_mv | 10.1038/s41433-024-03110-4 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3051937606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3051937606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-978850c30178279d1790daf5d81b8439542c5ff3d6059a071334ac8bf47f9a8d3</originalsourceid><addsrcrecordid>eNp9kcGK1TAUhosoznX0BVxIwI2batIkbeNOLle9MKCMCu7CaXLa6dA2NUnF2bn1nXwan8TUXhVcuDqQ8_3_-cmfZQ8Zfcoor58FwQTnOS1ETjljNBe3sh0TVZlLIcXtbEeVpHlRFB_PsnshXFOalhW9m53xumJUcbXLvh_HGUwkriXRI0QCkyX4JWIaxvcRfQ_ETWT2bnY-9m4KJF4lzsBEGjyhaAm0iSWDA9tPHZmvIOBqWvz4-m3s0nboG_QG55jk6GG-Ia3zZEL3GYJZBvAEOiQeB4jJbYTtzWKHU8LXw8_J28vD_vjuQC5xzULk_exOC0PAB6d5nn14eXi_f51fvHl13L-4yA0vypirqq4lNZyyqi4qZVmlqIVW2po1teBKisLItuW2pFIBrRjnAkzdtKJqFdSWn2dPNt_0C58WDFGPfTA4DJDyL0FzKpniVUnLhD7-B712i59SOr1WxDjjUiaq2CjjXQgeWz37fgR_oxnVa7d661anbvWvbrVIokcn66UZ0f6R_C4zAXwDQlpNHfq_t_9j-xM__7Ey</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3110131355</pqid></control><display><type>article</type><title>Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5</title><source>Springer Nature</source><creator>Thottarath, Sridevi ; Gurudas, Sarega ; Chandak, Swati ; Patel, Praveen J. ; Kotagiri, Ajay ; Pearce, Ian ; McKibbin, Martin ; Menon, Geeta ; Burton, Benjamin J. L. ; Talks, James ; Grabowska, Anna ; Ghanchi, Faruque ; Gale, Richard ; Karatsai, Eleni ; Chandra, Shruti ; Sivaprasad, Sobha</creator><creatorcontrib>Thottarath, Sridevi ; Gurudas, Sarega ; Chandak, Swati ; Patel, Praveen J. ; Kotagiri, Ajay ; Pearce, Ian ; McKibbin, Martin ; Menon, Geeta ; Burton, Benjamin J. L. ; Talks, James ; Grabowska, Anna ; Ghanchi, Faruque ; Gale, Richard ; Karatsai, Eleni ; Chandra, Shruti ; Sivaprasad, Sobha</creatorcontrib><description>Objective
To study the impact of definitions of various treatment extension criteria on the proportion of patients who could be extended at their first visit after the loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration (nAMD).
Methods
Patients with nAMD initiated on the loading phase of three intravitreal doses of 2 mg aflibercept in routine clinical practice were recruited from December 2019 to August 2021. The response to the loading phase was assessed at approximately 8 weeks post-loading (up to 140 days from first injection) based on different definitions of response. The proportion of patients that qualify for interval extension based on different clinical trial criteria was also evaluated.
Results
A total of 722 patients with visual acuity (VA) and optical coherence tomography (OCT) scans done at all 4 visits were included. Of these 32.4% of eyes responded with complete macular fluid resolution after the first injection with no recurrence through the loading phase (super-responders) while 26.9% had persistent macular fluid in all 4 visits (true non-responders). The rest were considered suboptimal responders. Change in VA showed marked variations within each of these categories of fluid resolution. For extension of next treatment interval, if presence of any macular fluid at the post-loading visit is the only criteria considered, about 50% could be extended to 8 weeks. If both VA worsening by ≥5 letters and a > 25 μm increase in central sub-field thickness (CST) are considered, 90% will be eligible for interval extension.
Conclusion
Clinical trial designs and pre-defined treatment extension/shortening criteria determine the proportion of patients requiring treatment in the post-loading visit. The short and long-term impact of interval extension immediate post-loading on visual outcome in clinical practice is unknown.</description><identifier>ISSN: 0950-222X</identifier><identifier>ISSN: 1476-5454</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/s41433-024-03110-4</identifier><identifier>PMID: 38710939</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/3161/3175 ; 706/648/160 ; Acuity ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - therapeutic use ; Clinical medicine ; Clinical trials ; Female ; Humans ; Intravitreal Injections ; Laboratory Medicine ; Macular degeneration ; Male ; Medicine ; Medicine & Public Health ; Ophthalmology ; Patients ; Pharmaceutical Sciences/Technology ; Receptors, Vascular Endothelial Growth Factor - administration & dosage ; Receptors, Vascular Endothelial Growth Factor - therapeutic use ; Recombinant Fusion Proteins - administration & dosage ; Recombinant Fusion Proteins - therapeutic use ; Surgery ; Surgical Oncology ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity - physiology ; Wet Macular Degeneration - diagnosis ; Wet Macular Degeneration - drug therapy ; Wet Macular Degeneration - physiopathology</subject><ispartof>Eye (London), 2024-10, Vol.38 (14), p.2737-2743</ispartof><rights>The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-978850c30178279d1790daf5d81b8439542c5ff3d6059a071334ac8bf47f9a8d3</cites><orcidid>0000-0003-4388-243X ; 0000-0001-8255-6253 ; 0000-0002-2634-9775 ; 0000-0001-8682-4067 ; 0000-0001-9579-9078 ; 0000-0002-3053-2142 ; 0000-0002-4448-8162</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38710939$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thottarath, Sridevi</creatorcontrib><creatorcontrib>Gurudas, Sarega</creatorcontrib><creatorcontrib>Chandak, Swati</creatorcontrib><creatorcontrib>Patel, Praveen J.</creatorcontrib><creatorcontrib>Kotagiri, Ajay</creatorcontrib><creatorcontrib>Pearce, Ian</creatorcontrib><creatorcontrib>McKibbin, Martin</creatorcontrib><creatorcontrib>Menon, Geeta</creatorcontrib><creatorcontrib>Burton, Benjamin J. L.</creatorcontrib><creatorcontrib>Talks, James</creatorcontrib><creatorcontrib>Grabowska, Anna</creatorcontrib><creatorcontrib>Ghanchi, Faruque</creatorcontrib><creatorcontrib>Gale, Richard</creatorcontrib><creatorcontrib>Karatsai, Eleni</creatorcontrib><creatorcontrib>Chandra, Shruti</creatorcontrib><creatorcontrib>Sivaprasad, Sobha</creatorcontrib><title>Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Objective
To study the impact of definitions of various treatment extension criteria on the proportion of patients who could be extended at their first visit after the loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration (nAMD).
Methods
Patients with nAMD initiated on the loading phase of three intravitreal doses of 2 mg aflibercept in routine clinical practice were recruited from December 2019 to August 2021. The response to the loading phase was assessed at approximately 8 weeks post-loading (up to 140 days from first injection) based on different definitions of response. The proportion of patients that qualify for interval extension based on different clinical trial criteria was also evaluated.
Results
A total of 722 patients with visual acuity (VA) and optical coherence tomography (OCT) scans done at all 4 visits were included. Of these 32.4% of eyes responded with complete macular fluid resolution after the first injection with no recurrence through the loading phase (super-responders) while 26.9% had persistent macular fluid in all 4 visits (true non-responders). The rest were considered suboptimal responders. Change in VA showed marked variations within each of these categories of fluid resolution. For extension of next treatment interval, if presence of any macular fluid at the post-loading visit is the only criteria considered, about 50% could be extended to 8 weeks. If both VA worsening by ≥5 letters and a > 25 μm increase in central sub-field thickness (CST) are considered, 90% will be eligible for interval extension.
Conclusion
Clinical trial designs and pre-defined treatment extension/shortening criteria determine the proportion of patients requiring treatment in the post-loading visit. The short and long-term impact of interval extension immediate post-loading on visual outcome in clinical practice is unknown.</description><subject>692/699/3161/3175</subject><subject>706/648/160</subject><subject>Acuity</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Female</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Laboratory Medicine</subject><subject>Macular degeneration</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Receptors, Vascular Endothelial Growth Factor - administration & dosage</subject><subject>Receptors, Vascular Endothelial Growth Factor - therapeutic use</subject><subject>Recombinant Fusion Proteins - administration & dosage</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Visual Acuity - physiology</subject><subject>Wet Macular Degeneration - diagnosis</subject><subject>Wet Macular Degeneration - drug therapy</subject><subject>Wet Macular Degeneration - physiopathology</subject><issn>0950-222X</issn><issn>1476-5454</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kcGK1TAUhosoznX0BVxIwI2batIkbeNOLle9MKCMCu7CaXLa6dA2NUnF2bn1nXwan8TUXhVcuDqQ8_3_-cmfZQ8Zfcoor58FwQTnOS1ETjljNBe3sh0TVZlLIcXtbEeVpHlRFB_PsnshXFOalhW9m53xumJUcbXLvh_HGUwkriXRI0QCkyX4JWIaxvcRfQ_ETWT2bnY-9m4KJF4lzsBEGjyhaAm0iSWDA9tPHZmvIOBqWvz4-m3s0nboG_QG55jk6GG-Ia3zZEL3GYJZBvAEOiQeB4jJbYTtzWKHU8LXw8_J28vD_vjuQC5xzULk_exOC0PAB6d5nn14eXi_f51fvHl13L-4yA0vypirqq4lNZyyqi4qZVmlqIVW2po1teBKisLItuW2pFIBrRjnAkzdtKJqFdSWn2dPNt_0C58WDFGPfTA4DJDyL0FzKpniVUnLhD7-B712i59SOr1WxDjjUiaq2CjjXQgeWz37fgR_oxnVa7d661anbvWvbrVIokcn66UZ0f6R_C4zAXwDQlpNHfq_t_9j-xM__7Ey</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>Thottarath, Sridevi</creator><creator>Gurudas, Sarega</creator><creator>Chandak, Swati</creator><creator>Patel, Praveen J.</creator><creator>Kotagiri, Ajay</creator><creator>Pearce, Ian</creator><creator>McKibbin, Martin</creator><creator>Menon, Geeta</creator><creator>Burton, Benjamin J. L.</creator><creator>Talks, James</creator><creator>Grabowska, Anna</creator><creator>Ghanchi, Faruque</creator><creator>Gale, Richard</creator><creator>Karatsai, Eleni</creator><creator>Chandra, Shruti</creator><creator>Sivaprasad, Sobha</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4388-243X</orcidid><orcidid>https://orcid.org/0000-0001-8255-6253</orcidid><orcidid>https://orcid.org/0000-0002-2634-9775</orcidid><orcidid>https://orcid.org/0000-0001-8682-4067</orcidid><orcidid>https://orcid.org/0000-0001-9579-9078</orcidid><orcidid>https://orcid.org/0000-0002-3053-2142</orcidid><orcidid>https://orcid.org/0000-0002-4448-8162</orcidid></search><sort><creationdate>20241001</creationdate><title>Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5</title><author>Thottarath, Sridevi ; Gurudas, Sarega ; Chandak, Swati ; Patel, Praveen J. ; Kotagiri, Ajay ; Pearce, Ian ; McKibbin, Martin ; Menon, Geeta ; Burton, Benjamin J. L. ; Talks, James ; Grabowska, Anna ; Ghanchi, Faruque ; Gale, Richard ; Karatsai, Eleni ; Chandra, Shruti ; Sivaprasad, Sobha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-978850c30178279d1790daf5d81b8439542c5ff3d6059a071334ac8bf47f9a8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>692/699/3161/3175</topic><topic>706/648/160</topic><topic>Acuity</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Female</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Laboratory Medicine</topic><topic>Macular degeneration</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Receptors, Vascular Endothelial Growth Factor - administration & dosage</topic><topic>Receptors, Vascular Endothelial Growth Factor - therapeutic use</topic><topic>Recombinant Fusion Proteins - administration & dosage</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Visual Acuity - physiology</topic><topic>Wet Macular Degeneration - diagnosis</topic><topic>Wet Macular Degeneration - drug therapy</topic><topic>Wet Macular Degeneration - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thottarath, Sridevi</creatorcontrib><creatorcontrib>Gurudas, Sarega</creatorcontrib><creatorcontrib>Chandak, Swati</creatorcontrib><creatorcontrib>Patel, Praveen J.</creatorcontrib><creatorcontrib>Kotagiri, Ajay</creatorcontrib><creatorcontrib>Pearce, Ian</creatorcontrib><creatorcontrib>McKibbin, Martin</creatorcontrib><creatorcontrib>Menon, Geeta</creatorcontrib><creatorcontrib>Burton, Benjamin J. L.</creatorcontrib><creatorcontrib>Talks, James</creatorcontrib><creatorcontrib>Grabowska, Anna</creatorcontrib><creatorcontrib>Ghanchi, Faruque</creatorcontrib><creatorcontrib>Gale, Richard</creatorcontrib><creatorcontrib>Karatsai, Eleni</creatorcontrib><creatorcontrib>Chandra, Shruti</creatorcontrib><creatorcontrib>Sivaprasad, Sobha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thottarath, Sridevi</au><au>Gurudas, Sarega</au><au>Chandak, Swati</au><au>Patel, Praveen J.</au><au>Kotagiri, Ajay</au><au>Pearce, Ian</au><au>McKibbin, Martin</au><au>Menon, Geeta</au><au>Burton, Benjamin J. L.</au><au>Talks, James</au><au>Grabowska, Anna</au><au>Ghanchi, Faruque</au><au>Gale, Richard</au><au>Karatsai, Eleni</au><au>Chandra, Shruti</au><au>Sivaprasad, Sobha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2024-10-01</date><risdate>2024</risdate><volume>38</volume><issue>14</issue><spage>2737</spage><epage>2743</epage><pages>2737-2743</pages><issn>0950-222X</issn><issn>1476-5454</issn><eissn>1476-5454</eissn><abstract>Objective
To study the impact of definitions of various treatment extension criteria on the proportion of patients who could be extended at their first visit after the loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration (nAMD).
Methods
Patients with nAMD initiated on the loading phase of three intravitreal doses of 2 mg aflibercept in routine clinical practice were recruited from December 2019 to August 2021. The response to the loading phase was assessed at approximately 8 weeks post-loading (up to 140 days from first injection) based on different definitions of response. The proportion of patients that qualify for interval extension based on different clinical trial criteria was also evaluated.
Results
A total of 722 patients with visual acuity (VA) and optical coherence tomography (OCT) scans done at all 4 visits were included. Of these 32.4% of eyes responded with complete macular fluid resolution after the first injection with no recurrence through the loading phase (super-responders) while 26.9% had persistent macular fluid in all 4 visits (true non-responders). The rest were considered suboptimal responders. Change in VA showed marked variations within each of these categories of fluid resolution. For extension of next treatment interval, if presence of any macular fluid at the post-loading visit is the only criteria considered, about 50% could be extended to 8 weeks. If both VA worsening by ≥5 letters and a > 25 μm increase in central sub-field thickness (CST) are considered, 90% will be eligible for interval extension.
Conclusion
Clinical trial designs and pre-defined treatment extension/shortening criteria determine the proportion of patients requiring treatment in the post-loading visit. The short and long-term impact of interval extension immediate post-loading on visual outcome in clinical practice is unknown.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38710939</pmid><doi>10.1038/s41433-024-03110-4</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4388-243X</orcidid><orcidid>https://orcid.org/0000-0001-8255-6253</orcidid><orcidid>https://orcid.org/0000-0002-2634-9775</orcidid><orcidid>https://orcid.org/0000-0001-8682-4067</orcidid><orcidid>https://orcid.org/0000-0001-9579-9078</orcidid><orcidid>https://orcid.org/0000-0002-3053-2142</orcidid><orcidid>https://orcid.org/0000-0002-4448-8162</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0950-222X |
ispartof | Eye (London), 2024-10, Vol.38 (14), p.2737-2743 |
issn | 0950-222X 1476-5454 1476-5454 |
language | eng |
recordid | cdi_proquest_miscellaneous_3051937606 |
source | Springer Nature |
subjects | 692/699/3161/3175 706/648/160 Acuity Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Clinical medicine Clinical trials Female Humans Intravitreal Injections Laboratory Medicine Macular degeneration Male Medicine Medicine & Public Health Ophthalmology Patients Pharmaceutical Sciences/Technology Receptors, Vascular Endothelial Growth Factor - administration & dosage Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - therapeutic use Surgery Surgical Oncology Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology |
title | Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A45%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20treat%20and%20extend%20criteria%20on%20proportions%20that%20can%20be%20extended%20after%20loading%20phase%20of%202%E2%80%89mg%20aflibercept%20therapy%20for%20neovascular%20age%20related%20macular%20degeneration:%20PRECISE%20Report%205&rft.jtitle=Eye%20(London)&rft.au=Thottarath,%20Sridevi&rft.date=2024-10-01&rft.volume=38&rft.issue=14&rft.spage=2737&rft.epage=2743&rft.pages=2737-2743&rft.issn=0950-222X&rft.eissn=1476-5454&rft_id=info:doi/10.1038/s41433-024-03110-4&rft_dat=%3Cproquest_cross%3E3051937606%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c326t-978850c30178279d1790daf5d81b8439542c5ff3d6059a071334ac8bf47f9a8d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3110131355&rft_id=info:pmid/38710939&rfr_iscdi=true |